Products Categories
| CAS No.: | 1809249-37-3 |
|---|---|
| Name: | Remdesivir |
| Molecular Structure: | |
|
|
|
| Formula: | C27H35N6O8P |
| Molecular Weight: | 602.584 |
| Density: | 1.47±0.1 g/cm3(Predicted) |
| PSA: | 213.36000 |
| LogP: | 3.28428 |
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 211914-50-0N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-(2-pyridinyl)-beta-alanine ethyl ester hydrochloride
- 240444-70-62,3,5,6-Tetrafluor-4-(methoxymethyl)benzyl-2,2-dimethyl-3-(prop-1-en-1-yl)cyclopropancarboxylat
- 1809249-37-3
(2S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
| Conditions | Yield |
|---|---|
| With hydrogenchloride In water; acetone at 20℃; for 3h; pH=3 - 4; Reagent/catalyst; | 91% |
| With hydrogenchloride In tetrahydrofuran; water at 0 - 25℃; for 8h; | 73% |
| With hydrogenchloride In tetrahydrofuran; water at 20℃; Inert atmosphere; | 69% |
- 1191237-69-0
(2R,3R,4S,5R)‑2‑(4‑aminopyrrolo[1,2‑f][1,2,4]triazin‑7‑yl)‑3,4‑dihydroxy‑5‑(hydroxymethyl)tetrahydrofuran‑2‑carbonitrile
- 1809249-37-3
(2S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
| Conditions | Yield |
|---|---|
| Stage #1: (2R,3R,4S,5R)‑2‑(4‑aminopyrrolo[1,2‑f][1,2,4]triazin‑7‑yl)‑3,4‑dihydroxy‑5‑(hydroxymethyl)tetrahydrofuran‑2‑carbonitrile With titanium(IV) isopropylate; tert-butylmagnesium chloride In tetrahydrofuran at -10 - 0℃; for 0.5h; Stage #2: C21H26N3O9P In tetrahydrofuran at -10 - 20℃; Solvent; Reagent/catalyst; | 86.2% |
- 1809249-37-3
(2S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
| Conditions | Yield |
|---|---|
| at 60℃; | 84% |
- 1191237-69-0
(2R,3R,4S,5R)‑2‑(4‑aminopyrrolo[1,2‑f][1,2,4]triazin‑7‑yl)‑3,4‑dihydroxy‑5‑(hydroxymethyl)tetrahydrofuran‑2‑carbonitrile
- 1809249-37-3
(2S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
| Conditions | Yield |
|---|---|
| With diisopropylamine; zinc dibromide In tetrahydrofuran at 20℃; for 4h; Reagent/catalyst; Solvent; Inert atmosphere; Molecular sieve; | 81% |
- 1355049-92-1
2-ethylbutyl (2S)-2-{[chloro(phenoxy)phosphoryl]amino}propanoate
- 1191237-80-5
(3αR,4R,6R,6αR)-4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carbonitrile
- 1809249-37-3
(2S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
| Conditions | Yield |
|---|---|
| Stage #1: (3αR,4R,6R,6αR)-4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carbonitrile With 2,6-dimethylpyridine; C17H21N3O2 In dichloromethane at -20 - 20℃; for 0.333333h; Inert atmosphere; Molecular sieve; Stage #2: 2-ethylbutyl (2S)-2-{[chloro(phenoxy)phosphoryl]amino}propanoate In dichloromethane at -20 - 20℃; for 24h; Inert atmosphere; Molecular sieve; Stage #3: With toluene-4-sulfonic acid In methanol at 20℃; for 24h; Inert atmosphere; | 73% |
| Multi-step reaction with 2 steps 1.1: C17H21N3O2; 2,6-dimethylpyridine / dichloromethane / 0.33 h / -40 - 20 °C / Inert atmosphere; Molecular sieve 1.2: 24 h / 4 - 20 °C / Inert atmosphere; Molecular sieve 2.1: hydrogenchloride / tetrahydrofuran; water / 20 °C / Inert atmosphere View Scheme | |
| Multi-step reaction with 2 steps 1.1: C17H21N3O2; 2,6-dimethylpyridine / dichloromethane / 0.33 h / -40 - 20 °C / Inert atmosphere; Molecular sieve 1.2: 24 h / 4 - 20 °C / Inert atmosphere; Molecular sieve 2.1: hydrogenchloride / tetrahydrofuran; water / 20 °C / Inert atmosphere View Scheme | |
| Stage #1: (3αR,4R,6R,6αR)-4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carbonitrile With tert-butylmagnesium chloride In tetrahydrofuran at -40 - 30℃; Stage #2: 2-ethylbutyl (2S)-2-{[chloro(phenoxy)phosphoryl]amino}propanoate In tetrahydrofuran at -40 - 10℃; | 100 mg |
- 1191237-69-0
(2R,3R,4S,5R)‑2‑(4‑aminopyrrolo[1,2‑f][1,2,4]triazin‑7‑yl)‑3,4‑dihydroxy‑5‑(hydroxymethyl)tetrahydrofuran‑2‑carbonitrile
- 1809249-37-3
(2S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
| Conditions | Yield |
|---|---|
| With triethylamine; zinc(II) chloride In tetrahydrofuran at 65℃; for 25h; Inert atmosphere; | 44% |
- 1191237-69-0
(2R,3R,4S,5R)‑2‑(4‑aminopyrrolo[1,2‑f][1,2,4]triazin‑7‑yl)‑3,4‑dihydroxy‑5‑(hydroxymethyl)tetrahydrofuran‑2‑carbonitrile
- 1809249-37-3
(2S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
| Conditions | Yield |
|---|---|
| With N-ethyl-N,N-diisopropylamine; magnesium chloride In 1,4-dioxane at 55℃; for 25h; Inert atmosphere; | 42% |
- 1191237-69-0
(2R,3R,4S,5R)‑2‑(4‑aminopyrrolo[1,2‑f][1,2,4]triazin‑7‑yl)‑3,4‑dihydroxy‑5‑(hydroxymethyl)tetrahydrofuran‑2‑carbonitrile
- 1809249-37-3
(2S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
| Conditions | Yield |
|---|---|
| With potassium carbonate; zinc dibromide In tert-butyl methyl ether at 75℃; for 25h; Inert atmosphere; | 40.5% |
- 1809249-37-3
(2S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
| Conditions | Yield |
|---|---|
| Multi-step reaction with 2 steps 1: tert-butylmagnesium chloride / tetrahydrofuran / 16 h / -10 - 5 °C 2: hydrogenchloride; water / 72 h / 0 - 20 °C View Scheme |
- 1809249-37-3
(2S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
| Conditions | Yield |
|---|---|
| Multi-step reaction with 2 steps 1: magnesium chloride; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 21 h / 50 °C 2: hydrogenchloride; water / 72 h / 0 - 20 °C View Scheme |
What can I do for you?
Get Best Price
Specification
Product Description:
Novel inhibitor of the replication of several taxonomically diverse RNA viruses such as Middle East respiratory syndrome virus, Ebola virus, Lassa fever virus, Junin virus and respiratory syncytial virus, while having low cytotoxicity in a wide-range of cell lines
Remdesivir Properties
Background Information
Remdesivir is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for ARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells.
Remdesivir, also known as GS-5734, is an antiviral drug, a novel nucleotide analog prodrug. It was developed by Gilead Sciences as a treatment for filovirus infections such as Ebola virus disease and Marburg virus, though it has subsequently also been found to show reasonable antiviral activity against more distantly related viruses such as respiratory syncytial virus, Junin virus, Lassa fever virus, and MERS-coronavirus. GS-5734 was rapidly pushed through clinical trials due to the 2013–2016 West African Ebola virus epidemic crisis, eventually being used in at least one human patient despite its early development stage at the time. Preliminary results have been promising, and further clinical trials are planned.
GS-5734 (Remdesivir) is a monophosphoramidate prodrug of adenosine analogue that exhibits antiviral activity against multiple variants of EBOV (EC50=70-140 nM) and other filoviruses (EC50=0.019-1.48 uM) in cell-based assays; suppresses EBOV replication and protects 100% of EBOV-infected animals against lethal disease, ameliorating clinical disease signs and pathophysiological markers.
InChI
InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1 InChIKey
RWWYLEGWBNMMLJ-YSOARWBDSA-N
Smiles
CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)c2ccc3c(N)ncnn23)Oc4ccccc4